VEW 2022: New dark adaptation modality and other pipeline updates from Heru

Video

Brandon Barber, chief marketing officer at Heru, shares about the company's new dark adaptation modality, which they announced during the 2022 Vision Expo West, as well as other advancements in the pipeline.

Brandon Barber, chief marketing officer for Heru, sat down with Optometry Times® editor, Kassi Jackson, to share about the company's new AMD portfolio expansion, and other items in the pipeline.

Related: Heru expands AMD portfolio with new launch

Key takeaways from the interview:

  • Heru's latest dark adaptation modality. This new technology allows Heru to offer the only AMD portfolio available on the market.
  • The company is providing cloud-based updates for their platform on a weekly and monthly basis to improve customer and patient outcomes.
  • New therapeutic technology is coming out of their research facility in Bascom Palmer Eye Institute, including AR platform adaptations to improve eye defects that lead to limited vision for patients.
  • Barber said that in the next 24 to 36 months, there will be advancements in the areas of AR and VR.
  • These new and coming advancements improve patient experience, as well as will improve the ability for optometrists to "speed more patients through their practice," according to Barber.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
© 2025 MJH Life Sciences

All rights reserved.